RARE:NSD-Ultragenyx (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 55.22

Change

-1.54 (-2.71)%

Market Cap

USD 5.41B

Volume

0.43M

Analyst Target

USD 85.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing RARE

GNOM Global X Genomics & Biote.. 4.59 % 0.00 %

+0.16 (+-0.23%)

USD 0.08B
GNOG:LSE Global X Genomics & Biote.. 4.57 % 0.00 %

N/A

USD 6.06M
GN0M:XETRA Global X Genomics & Biote.. 4.48 % 0.00 %

-0.01 (-0.23%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.48 % 0.00 %

-0.02 (-0.23%)

USD 6.06M
BBP Virtus LifeSci Biotech Pr.. 1.98 % 0.79 %

+0.58 (+-0.23%)

USD 0.02B
WRNA:XETRA WisdomTree BioRevolution .. 1.75 % 0.00 %

+0.07 (+-0.23%)

USD 2.77M
IS0R:XETRA iShares High Yield Corpor.. 0.32 % 0.00 %

-0.17 (-0.23%)

USD 2.71B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.13 (+-0.23%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

-0.37 (-0.23%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.47% 70% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.47% 70% C- 72% C
Trailing 12 Months  
Capital Gain 57.01% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.01% 78% C+ 86% B+
Trailing 5 Years  
Capital Gain 29.93% 74% C 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.93% 73% C 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 10.54% 66% D+ 67% D+
Dividend Return 10.54% 66% D+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.36% 45% F 24% F
Risk Adjusted Return 14.37% 74% C 50% F
Market Capitalization 5.41B 96% N/A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector